Cholestagel (colesevelam) is a nonabsorbed anion exchanger, approved to reduce cholesterol in patients with hypercholesterolemia.
The drug has been well studied together with statins and can therefore be used in patients that do not achieve an adequate reduction of cholesterol on statins and changes of diet. However ezetimibe (Ezetrol) is much less expensive even though there isn’t any difference in efficiency and side effects.
Cholestagel has also been studied along with ezetimibe in patients, that do not tolerate statins, but the effect is lesser than ezemitibe. Cholestagel has finally been studied as monotherapy in patients that do not achieve an effect from changes of diet and who are restricted in the use of statins.
The side effects of cholesterol are primarily gastrointestinal disturbance.
Cholestagel has not been compared with other anion exchangers. One daily dose of Cholestagel costs 43,90 D.kr, which is much more expensive than other anion exchangers.
Cholestagel, prescription only, was marketed the 22nd of October 2007. Cholestagel is not covered under the rules of general reimbursement.